Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: AgAuUSA who wrote (8025)	2/6/1998 1:55:00 PM
From: AgAuUSA	Respond to of 14328

1 dose of new drug keeps man HIV-free for a year Doctors wrestle with wide array of AIDS drugs Studies: It's dangerous to cut back on HIV drugs HIV drugs credited for saving lives in New York CHICAGO (February 5, 1998 4:55 p.m. EST) - A new treatment against the AIDS virus using a decades-old cancer drug has kept one man healthy for more than a year after he stopped taking the drugs, researchers said Thursday. "We were quite excited about this," Dr. Franco Lori, co-director of the Research Institute for Genetic and Human Therapy (RIGHT) at Georgetown University in Washington and Policlinico San Matteo in Pavia, Italy, told reporters at a conference in Chicago on HIV, the virus that causes AIDS. "The only three patients who have not rebounded after treatment is stopped are hydroxyurea patients," he said. Hydroxyurea, sold by Bristol-Myers Squibb as Hydrea, was developed as a cancer drug 35 years ago and is also used against sickle cell anemia. Lori's team did several tests involving "classic" HIV drugs such as ddI, (Bristol-Myer Squibb's Videx) plus a protease inhibitor and hydrea to 24 patients. The virus seemed to disappear. Using more sensitive tests, they found the virus in the lymph nodes of most of the patients. But a second test on 10 patients who had just become infected, and whose immune systems were thus not badly damaged, showed more dramatic effects. In two of the patients, no detectable virus could be found in the lymph nodes, and in one there was almost no virus seen in the lymph nodes even a year after he went off the drugs. Some patients showed a decreased white blood cell count, a team at the University of Texas reported. Hydroxyurea is known to affect bone marrow, and they said any bad effects stopped once the drug was discontinued. Dr. Jeffrey Galpin of Shared Medical Research in Tarzana, California and colleagues at RIGHT said a 28-week study of 42 patients showed that using hydroxyurea with ddI and d4T (Bristol's Zerit) stabilized the immune system. The number of CD4 cells -- the immune cells that HIV attack -- rebounded. In August 1997, Jorge Vila and colleagues at the Centre Hospitalier Universitaire in Grenoble, France reported that two patients who were given ddI and hydroxyurea showed no detectable levels of virus in their blood even 12 months after they stopped taking the drugs. A Swiss team said adding hydroxyurea to the mix might be a cost-effective way to give patients triple therapy. The drug is so old its patent has run out and it is therefore inexpensive. Other experts are intrigued but skeptical. "Hydroxyurea is certainly an interesting drug," said Dr. Charles Farthing of the AIDS Healthcare Foundation in Los Angeles. "But maybe they are just lucky." He and others said they would like to see further studies using more patients.